Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma

Background: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan, even though vandetanib for MTC and lenvatinib for MTC and ATC have been approved. Sorafenib is an oral multikinase inhibitor approv...

Full description

Saved in:
Bibliographic Details
Published in:Thyroid
Main Authors: Ito, Yasuhiro, Onoda, Naoyoshi, Ito, Ken-ichi, Sugitani, Iwao, Takahashi, Shunji, Yamaguchi, Iku, Kabu, Koki, Tsukada, Katsuya
Format: Artigo
Language:Inglês
Published: Mary Ann Liebert, Inc. 2017
Subjects:
Thyroid Cancer and Nodules
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5646744/
https://ncbi.nlm.nih.gov/pubmed/28635560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2016.0621
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items